Cost effectiveness of vaccination against pandemic influenza in European countries: Mathematical modelling analysis

BMJ (Online)

Volumn 345, Issue 7868, 2012, Pages

  Lugnér, Anna K ^a   Van Boven, Michiel ^a   De Vries, Robin ^b,c   Postma, Maarten J ^b   Wallinga, Jacco ^a,d  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c Roche Nederland   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ELDERLY CARE; GERMANY; HUMAN; INFANT; INFECTION SENSITIVITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; NETHERLANDS; PANDEMIC INFLUENZA; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; UNITED KINGDOM; VIRUS TRANSMISSION; BIOLOGICAL MODEL; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; ECONOMICS; EVALUATION; HEALTH CARE COST; INFLUENZA; INFLUENZA VIRUS A; METHODOLOGY; MIDDLE AGED; NEWBORN; PANDEMIC; STATISTICAL MODEL; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; GERMANY; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, ECONOMIC; NETHERLANDS; PANDEMICS; QUALITY-ADJUSTED LIFE YEARS; VACCINATION; YOUNG ADULT;

EID: 84864543092     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e4445     Document Type: Article

References (45)

1. Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004;159:623-33. (Pubitemid 38405377)
2. Mylius SD, Hagenaars TJ, Lugner AK, Wallinga J. Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine 2008;26:3742-9.
3. Longini IM Jr, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, et al. Containing pandemic influenza at the source. Science 2005;309:1083-7. (Pubitemid 41134467)
4. Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 2006;103:5935-40.
5. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 2006;442:448-52. (Pubitemid 44264793)
6. Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 2005;437:209-14. (Pubitemid 41294478)
7. Baguelin M, Hoek AJ, Jit M, Flasche S, White PJ, Edmunds WJ. Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine 2010;28:2370-84.
8. Lugner AK, Mylius SD, Wallinga J. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Econ 2010;19:518-31.
9. Sander B, Nizam A, Garrison LP Jr, Postma MJ, Halloran ME, Longini IM Jr. Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health 2009;12:226-33.
10. Wallinga J, Lipsitch M. How generation intervals shape the relationship between growth rates and reproductive numbers. Proc Biol Sci 2007;274:599-604. (Pubitemid 47055535)
11. Hahne S, Donker T, Meijer A, Timen A, van Steenbergen J, Osterhaus A, et al. Epidemiology and control of influenza A(H1N1)v in the Netherlands: the first 115 cases. Euro Surveill 2009;14(27).
12. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008;5:e74.
13. Van Genugten ML, Heijnen ML, Jager JC. Pandemic influenza and healthcare demand in the Netherlands: scenario analysis. Emerg Infect Dis 2003;9:531-8. (Pubitemid 36529510)
14. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518-27.
15. Wallinga J, van Boven M, Lipsitch M. Optimizing infectious disease interventions during an emerging epidemic. Proc Natl Acad Sci USA 2010;107:923-8.
16. Mulder J, Masurel N. Pre-epidemic antibody against 1957 strain of Asiatic influenza in serum of older people living in the Netherlands. Lancet 1958;1:810-4.
17. Miller M Viboud C, Simonsen L, Olson DR, Russell C. Mortality and morbidity burden associated with A/H1N1pdm influenza virus. Who is likely to be infected, experience clinical symptoms or die from the H1N1pdm 2009 pandemic virus? PLoS Currents: Influenza 2009;RRN1013.
18. NICE. Social value judgements: principles for the development of NICE guidance.
19. Casparie AF, van Hout BA, Simoons ML. [Guidelines and costs]. Ned Tijdschr Geneeskd 1998;142:2075-7.
20. Boersma C, Broere A, Postma MJ. Quantification of the potential impact of cost-effectiveness thresholds on Dutch drug expenditures using retrospective analysis. Value Health 2010;13:853-6.
21. Fukuda K Levandowski RA, Bridges CB, Cox NJ, eds. Inactivated influenza vaccines. Saunders, 2004.
22. Jordan WS Jr, Denny FW Jr, Badger GF, Curtiss C, Dingle JH, Oseasohn R, et al. A study of illness in a group of Cleveland families. XVII. The occurrence of Asian influenza. Am J Hyg 1958;68:190-212.
23. Baltussen RM, Reinders A, Sprenger MJ, Postma MJ, Jager JC, Ament AJ, et al. Estimating influenza-related hospitalization in The Netherlands. Epidemiol Infect 1998;121:129-38. (Pubitemid 28423338)
24. Oostenbrink JB Bouwmans CAM, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2004. [In Dutch]. Diemen: College voor zorgverzekeringen, 2004.
25. ISPOR. International Society for Pharmacoeconomics and Outcomes Research. 2009. www.ispor.org.
26. National Institute for Health and Clinical Excellence. The guidelines manual 2009. NICE, 2009.
27. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-89.
28. Melse JM, Essink-Bot ML, Kramers PG, Hoeymans N. A national burden of disease calculation: Dutch disability-adjusted life-years. Dutch Burden of Disease Group. Am J Public Health 2000;90:1241-7. (Pubitemid 30497377)
29. Postma MJ, Bos JM, van Gennep M, Jager JC, Baltussen R, Sprenger MJ. Economic evaluation of influenza vaccination. Assessment for The Netherlands. Pharmacoeconomics 1999;16(Suppl 1):33-40. (Pubitemid 29512630)
30. Sprenger MJ, Mulder PG, Beyer WE, Van Strik R, Masurel N. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989. Int J Epidemiol 1993;22:334-40.
31. Boelle PY, Ansart S, Cori A, Valleron AJ. Transmission parameters of the A/H1N1 (2009) influenza virus pandemic: a review. Influenza Other Respi Viruses 2011;5:306-16.
32. Prosser LA, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, et al. Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States. PLoS One 2011;6:e22308.
33. Sander B, Bauch CT, Fisman D, Fowler RA, Kwong JC, Maetzel A, et al. Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience. Vaccine 2010;28:6210-20.
34. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999;5:659-71. (Pubitemid 29493768)
35. Medlock J, Galvani AP. Optimizing influenza vaccine distribution. Science 2009;325:1705-8.
36. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012;7:e33536.
37. Partinen M, Saarenpää-Heikkilä O, Ilveskoski I, Hublin C, Linna M, Olsén P, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 2012;7:e33723.
38. StatistischeBundesamtDeutschland. Statistische Bundesamt Deutschland. 2009. www. genesis.destatis.de.
39. CBS. Statistics Netherlands: Statline. 2009. http://statline.cbs.nl/ statweb/.
40. Governments Actuary's Department, United Kingdom. 2009. www.gad.gov.uk
41. Aballea S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, et al. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health 200710:98-116.
42. Postma MJ, Jansema P, Scheijbeler HW, van Genugten ML. Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults. Vaccine 2005;23:5365-71. (Pubitemid 41579307)
43. Sander B, Hayden FG, Gyldmark M, Garrison LP Jr. Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. Pharmacoeconomics 2006;24:373-86.
44. Medicijnkosten. Drug costs. [In Dutch]. www.medicijnkosten.nl.
45. Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. Am J Epidemiol 2006;164:936-44. (Pubitemid 44729833)